Theorem Clinical Research continues to broaden its ability to help sponsors optimize trial conduct
Theorem Clinical Research
continues to broaden its ability to help sponsors optimize trial conduct, recently implementing SAS® Clinical Data Integration (SAS CDI), an innovative solution that automates the process of transforming, managing and verifying the creation of industry-mandated data standards.
SAS enables Theorem to automate the mapping of standard electronic data capture (EDC) databases and external data into standard data sets that are compliant with the Clinical Data Interchange Standards Consortium (CDISC). By using the technology for routine tasks, Theorem can now more easily manage standards throughout the entire life cycle.
Additionally, SAS CDI will be leveraged to automate Theorem’s clinical data warehouse and highly visual data discovery tools, reducing time and effort to obtain clinical data in real time.
“As an early supporter of CDISC, Theorem recognized the value that standardization and harmonization would bring to clinical data and reporting,” said Mark Penniston, executive vice president of clinical analytics for Theorem. “Now we’re able to combine our deep experience in developing CDISC-compliant data domains with SAS technology to produce high-quality, standardized data sets faster and more efficiently.”
Kecia Serwin, vice president,
SAS Health Care and Life Sciences
, commented, “We’re delighted that Theorem has joined the list of leading life science organizations who’ve chosen SAS to streamline standards adoption in drug development processes.”
As a
CDISC Registered Solutions Provider,
Theorem was among the first global contract research organizations to execute a CDISC-compliant submission in 2004 and has created more than 50,000 CDISC-compliant data sets to date.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.